{
    "nct_id": "NCT05253495",
    "official_title": "Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma",
    "inclusion_criteria": "* Newly diagnosed patients with histologically or cytologically proven newly diagnosed MB-NHL or cHL according to WHO Classification who meet the following criteria are eligible:\n\nCOHORT I:\n\nBurkitt lymphoma (ICD-O 9687/3) Burkitt-like lymphoma with 11q aberration (ICD-O 9687/3) Diffuse large B-cell lymphoma, NOS (ICD-O 9680/3) High grade B-cell lymphoma (ICD-O 9680/3)\n\nCOHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration) (GROUP B)61\n\nCOHORT Ib: any CNS involvement and/or BM involvement (≥ 25% lymphoma cells) (GROUP C)61 OR patients with less than 20% tumor size reduction post chemotherapy with cyclophosphamide, dexamethasone, vincristine (DOC Reduction for Cohort Ia).\n\nCOHORT II Classical Hodgkin lymphoma (ICD-O 9650/3, 9663/3, 9651/3, 9652/3, 9653/3)\n\nCOHORT IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK)\n\nCOHORT IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)\n\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 3 Years\nMust have maximum age of 39 Years",
    "exclusion_criteria": "* Primary mediastinal B-cell lymphoma (PMBL)\n* T-cell/histiocyte-rich large B-cell lymphoma\n* Gray zone lymphoma\n* Follicular lymphoma\n* Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)\n* Posttransplant lymphoproliferative lymphoma (PTLD)",
    "miscellaneous_criteria": ""
}